poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

Benzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PALI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

    Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.

    PALI
  3. Na

    Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

    Palisade Bio announced Health Canada's clearance of its Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance expands the study's geographic reach alongside prior U.S. regulatory approval. The company expects to begin patient dosing in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.

    PALI